Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remsima in Resistant Hidradenitis Suppurativa
NCT05663268Phase 1Completed
- Sponsor
- Services Institute of Medical Sciences
- Start
- Oct 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of infliximab in hidradenitis suppurativa (HS), sponsored by Services Institute of Medical Sciences. Primary endpoints: Hidradenitis Suppurativa Clinical Response at 24 weeks and Dermatology Life Quality Index at 24 weeks. Started Oct 2022; status: completed.
02
Drugs
infliximab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05663268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663268.